Legendary game show host Wink Martindale passed away at 91 due to lymphoma Learn about lymphoma’s warning signs and the ...

Find out how Gylden Pharma’s gold nanoparticle platform delivers targeted T cell immunity – providing a precise and durable defence against complex infectious diseases. In the fast-moving world of ...

PRESENTED at EBMT 2025 Annual Meeting, a new study explored the long-term effectiveness of chimeric antigen receptor (CAR)-T cell cocktail therapy for patients with relapsed/refractory diffuse large B ...

we found that these tumor cells were all positive for the T-cell antigens CD2 and CD3 and negative for CD8 and CD56. Particularly, the lymphoma cells were positive for CD20 while other B-cell antigens ...

or CAR T cell therapy, where a patient's immune cells are taken out, grown and modified to specifically target certain cancers such as the aggressive lymphoma Cannella had. When he was first ...

This trial enrolled 37 adult patients with CD30-positive Hodgkin lymphoma and five with T-cell lymphoma. Patients were heavily pretreated and were refractory to brentuximab vedotin and anti-PD1 ...

More information: Yago Nieto et al, Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial, Nature Medicine (2025). DOI: 10.1038/s41591-025 ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted clearance to initiate a global ...

In a strong validation of the company’s clinical trial, Imugene Ltd’s Phase 1b trial for its azer-cel off-the-shelf, allogeneic, CD19 CAR T therapy in relapsed/refractory diffuse large B-cell lymphoma ...

Skin (cutaneous) lymphomas often manifest as a skin rash. Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) ...

What Is Small Lymphocytic Lymphoma ... immunotherapy and stem cell transplant in the treatment for SLL. You get them through an IV. Chimeric antigen receptor (CAR) T-cell therapy.